Correction to: Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer

No authors listed

Published Erratum

No authors listed. J Natl Cancer Inst. 2023.

. 2023 Jun 8;115(6):773.

doi: 10.1093/jnci/djad084.

No abstract available

Erratum for

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, Deng Y, Zhu XQ, Liu H, Pan HX, Yang L, Bai HS, Luo X, Guo Y, Zhou MX, Sun YM, Zhang ZC, Li SM, Cheng X, Tan BX, Han LF, Liu YY, Zhang K, Zeng FX, Jia L, Hao XB, Wang YY, Feng G, Xie K, Lu Y, Zeng M. Wang XS, et al. J Natl Cancer Inst. 2023 Jun 8;115(6):742-748. doi: 10.1093/jnci/djac015. J Natl Cancer Inst. 2023. PMID: 35094066 Free PMC article. Clinical Trial.
Expression of Concern to: Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer.
[No authors listed] [No authors listed] J Natl Cancer Inst. 2023 Jun 8;115(6):769. doi: 10.1093/jnci/djac065. J Natl Cancer Inst. 2023. PMID: 35362056 Free PMC article. No abstract available.